Literature DB >> 30439341

Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Valerie J Kinchen1, Muhammad N Zahid2, Andrew I Flyak3, Mary G Soliman1, Gerald H Learn4, Shuyi Wang2, Edgar Davidson5, Benjamin J Doranz5, Stuart C Ray6, Andrea L Cox6, James E Crowe7, Pamela J Bjorkman3, George M Shaw2, Justin R Bailey8.   

Abstract

The role that broadly neutralizing antibodies (bNAbs) play in natural clearance of human hepatitis C virus (HCV) infection and the underlying mechanisms remain unknown. Here, we investigate the mechanism by which bNAbs, isolated from two humans who spontaneously cleared HCV infection, contribute to HCV control. Using viral gene sequences amplified from longitudinal plasma of the two subjects, we found that these bNAbs, which target the front layer of the HCV envelope protein E2, neutralized most autologous HCV strains. Acquisition of resistance to bNAbs by some autologous strains was accompanied by progressive loss of E2 protein function, and temporally associated with HCV clearance. These data demonstrate that bNAbs can mediate clearance of human HCV infection by neutralizing infecting strains and driving escaped viruses to an unfit state. These immunopathologic events distinguish HCV from HIV-1 and suggest that development of an HCV vaccine may be achievable.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCV clearance; antibody specificity; binding sites; hepatitis C virus; immunologic memory; neutralizing antibodies

Mesh:

Substances:

Year:  2018        PMID: 30439341      PMCID: PMC6250073          DOI: 10.1016/j.chom.2018.10.012

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  39 in total

Review 1.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

2.  Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Authors:  Michelle C Sabo; Vincent C Luca; Jannick Prentoe; Sharon E Hopcraft; Keril J Blight; Minkyung Yi; Stanley M Lemon; Jonathan K Ball; Jens Bukh; Matthew J Evans; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection.

Authors:  K M Chang; R Thimme; J J Melpolder; D Oldach; J Pemberton; J Moorhead-Loudis; J G McHutchison; H J Alter; F V Chisari
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

4.  Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Authors:  Justin R Bailey; Lisa N Wasilewski; Anna E Snider; Ramy El-Diwany; William O Osburn; Zhenyong Keck; Steven K H Foung; Stuart C Ray
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

5.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

6.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

Review 7.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

8.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

Authors:  Kimberly A Dowd; Dale M Netski; Xiao-Hong Wang; Andrea L Cox; Stuart C Ray
Journal:  Gastroenterology       Date:  2009-03-17       Impact factor: 22.682

9.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

10.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

View more
  35 in total

1.  A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.

Authors:  Yimin Tong; Qingchao Li; Rui Li; Yongfen Xu; Yu Pan; Junqi Niu; Jin Zhong
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

3.  Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance.

Authors:  Valerie J Kinchen; Guido Massaccesi; Andrew I Flyak; Madeleine C Mankowski; Michelle D Colbert; William O Osburn; Stuart C Ray; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

4.  Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.

Authors:  Fang Chen; Kenna Nagy; Deborah Chavez; Shelby Willis; Ryan McBride; Erick Giang; Andrew Honda; Jens Bukh; Phillip Ordoukhanian; Jiang Zhu; Sharon Frey; Robert Lanford; Mansun Law
Journal:  Gastroenterology       Date:  2019-12-04       Impact factor: 22.682

5.  Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion.

Authors:  Eduardo Salinas; Maude Boisvert; Amit A Upadhyay; Nathalie Bédard; Sydney A Nelson; Julie Bruneau; Cynthia A Derdeyn; Joseph Marcotrigiano; Matthew J Evans; Steven E Bosinger; Naglaa H Shoukry; Arash Grakoui
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

6.  Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.

Authors:  Michelle D Colbert; Andrew I Flyak; Clinton O Ogega; Valerie J Kinchen; Guido Massaccesi; Mayda Hernandez; Edgar Davidson; Benjamin J Doranz; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 7.  Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion.

Authors:  Gisa Gerold; Rebecca Moeller; Thomas Pietschmann
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915

Review 8.  Immune system control of hepatitis C virus infection.

Authors:  Johnasha D Stuart; Eduardo Salinas; Arash Grakoui
Journal:  Curr Opin Virol       Date:  2020-11-01       Impact factor: 7.090

Review 9.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

Review 10.  Challenges and Promise of a Hepatitis C Virus Vaccine.

Authors:  Andrea L Cox
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.